56.5 F
Laguna Hills
Thursday, Feb 29, 2024
-Advertisement-

AEON Shares up on Phase 2 Results 

Says medication shown to be safe during 52-week trial 

Shares of Irvine-based AEON Biopharma Inc. (NYSE: AEON) jumped 9.8% in after-hours trading after reporting positive clinical data for its medication that treats cervical dystonia (CD) and posttraumatic stress disorder.

A poster titled, “Efficacy and Safety of ABP-450 (prabotulinumtoxinA) in Adults with Cervical Dystonia: Results From the Open-label Extension of a Phase 2 Trial,” was presented by Dr. Chad Oh, AEON’s chief medical officer at TOXINS 2024, a conference currently being held by the International Neurotoxin Association in Berlin.

Topline data from a recently completed open-label extension of the Phase 2 trial demonstrated that the company’s ABP-450 was generally safe and well tolerated in CD patients for up to four treatment cycles during the 52-week duration of the study.

The ABP-450 study was in adults with moderate to severe CD, a chronic and debilitating neurologic condition affecting the muscles of the neck

“We are excited to announce positive data,” AEON Chief Executive Marc Forth said in a statement.

He said the results support a proposed Phase 3 study that it will discuss with the FDA.

In regular trading before the annoucement, the shares were up 0.7% to $7.15 and a $266 million market cap.

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

Peter J. Brennan
Peter J. Brennan
Peter J. Brennan has been a journalist for 40 years. He spent a decade in Latin America covering wars, narcotic traffickers, earthquakes, and business. His resume includes 15 years at Bloomberg News where his headlines and articles sometimes moved the market caps of companies he covered by hundreds of millions of dollars. His articles have been published worldwide, including the New York Times and the Washington Post; he's appeared on CNN, CBC, BBC, and Bloomberg TV. He was awarded a Kiplinger Fellowship at The Ohio State University.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-